Munich, Germany – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, announced the appointment of renowned surgical and anatomical pathologist Dr. Ralf Huss as Chief Medical Officer (CMO). Professor Huss brings significant expertise in pathology and will play a key role in expanding Definiens’ leading position in image and data analysis for Digital Pathology in Life Sciences into Tissue Diagnostics and Clinical Digital Pathology.
“We are very pleased that Professor Huss is assuming the role of the Chief Medical Officer for Definiens. Professor Huss’ expertise will be invaluable in further strengthening Definiens’ leading role in quantitative digital pathology for life science research, tissue diagnostics development and clinical routine,” said Thomas Heydler, CEO of Definiens. “We’re thrilled to have a highly regarded industry luminary consult the leadership team who will build upon Definiens’ expertise in pathology following the closure of a recent financing round.”
Professor Huss has more than 20 years of training and experience in histopathology and cancer research, and served previously as Global Head of Histopathology and Tissue Biomarker at Roche Diagnostics, where he was involved in identifying new tissue biomarkers to stratify cancer patients as part of a global Personalized Healthcare strategy. Professor Huss also co-founded the biotech company APCETH for which he remains a member of the management team. In addition Professor Huss holds national and international academic appointments at the Ludwig-Maximilians-University Munich (Germany) and the Wake Forest Institute for Regenerative Medicine (USA).
“I am very pleased to advise Definiens and support the outstanding work the company is doing in the field of clinical digital pathology,” said Professor Huss. “Novel tissue diagnostics will be essential in bringing the vision of personalized medicine to fruition. Definiens leadership position in Image and Data Analysis in Life Sciences is a perfect starting point to advance the development of tissue and companion diagnostics, and to ultimately offer ground breaking solutions for Clinical Digital Pathology. I am very much looking forward to contributing to the company’s growth and innovation in the role of Chief Medical Officer.”
Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com.